indication

Bipolar I Disorder

Competitive landscape projected to LB-102’s launch window

as of 2026-07-01
Competitive set
8
8 approved · 0 pipeline
Next guided milestone
2027-02-01
LB-102 — Adjunctive MDD (Ph2) trial initiation
LB-102 protection (issued)
2037
+4 pending families to 2047

Projection timeline

actual past → guided future · protection walls overlaid
84 events
2020
2024
2028
2032
2036
2040
2044
2048
today
LB-102 launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
Phase 36 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugRecruiting
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 43 trials
OwnerEli Lilly and Company
Protection2041
drugRecruiting
Iloperidone
US-approved 2009 · FANAPT
Phase 43 trials
OwnerVanda Pharmaceuticals
Protection2031
drugRecruiting
Cariprazine (Vraylar)
US-approved 2015 · Vraylar
Phase 32 trials
OwnerForest Laboratories
Protection2030
drugCompleted
Asenapine
US-approved 2009 · SAPHRIS
Phase 11 trial
OwnerOrganon and Co
Protection2033
drugTerminated
Risperidone
US-approved 1993 · RISPERDAL
Phase 31 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugCompleted
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 31 trial
OwnerAstraZeneca
Protection—
drugCompleted
Lurasidone
US-approved 2010 · Latuda
Phase 21 trial
OwnerSumitomo Pharmaceuticals America
Protection2031

Market size

prevalence as a range, not a number